| ［1］ PérezTenorio G, Stl O, Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrinine treated patients［J］. Br J Cancer, 2002, 86(4): 540545. ［2］ Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer［J］. Nat Rev Cancer, 2009, 9(9): 631643. ［3］ Xu Y, Sun Q. Headway in resistance to endocrine therapy in breast cancer［J］. J Thorac Dis, 2010, 2(3): 171177. ［4］ Bachelot T, Bourgier C, Cropet C, et al. Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study［J］. J Clin Oncol, 2012, 30(22): 27182724. ［5］ Shibuya M. Vascular endothelial growth factordependent and independent regulation of angiogenesis［J］. BMB Rep, 2008, 41(4): 278286. ［6］ LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations［J］. Drug Resist Updat, 2008, 11(12): 3250. ［7］ Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2overexpressing metastatic breast cancer who progressed on trastuzumabbased therapy［J］. J Clin Oncol, 2011, 29(23): 31263132. ［8］ De Laurentiis M, Arpino G, Massrelli E, et al. A metaanalysis on the interaction between HER2 expression and response to endocrine treatment in advanced breast cancer［J］. Clin Cancer Res, 2005, 11(13): 47414748. ［9］ Montemurro F, Rossi V, Cossu Rocca M, et al. Hormonereceptor expression and activity of trastuzumab with chemotherapy in HER2positive advanced breast cancer patients［J］. Cancer, 2012, 118(1): 1726. ［10］ Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase Ⅲ TAnDEM study［J］. J Clin Oncol, 2009, 27(33): 55295537. |
